Transgene SA · EURONEXT:TNG
Transgene SA — Investor Presentation (June 2005)
36 slides from Transgene SA's investor presentation, June 2005
Slide 1: Transgene: New management – New strategy – New future
TRANSGENE New management – New strategy – New future June 2005 1 transgene
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements, including statements regarding Transgene’s objectives for progress in its clinical trials and product candidate development. Statements that are not historical facts are based on the Company's current expectations, beli
Slide 3: Agenda
Agenda § KEY DATA § TRANSGENE STRATEGIC DIRECTION • Transgene transformed • Transgene in 2007 • Short term objectives § THE CLINICAL PIPELINE • The pipeline today • New clinical data § 2004 FINANCIAL RESULTS § CONCLUSION 3 transgene
Slide 4: Key Dates
Key Dates § 1979 Foundation § 1979 Contract-research organization § 1992 Focus on gene transfer technology § 1995 Completion of manufacturing facility (GMP) § 2001 Focus on drug development, cancer § 2005 Broad pipeline of Phase I & II therapeutic vaccines in cancer and infectious diseases § May 200
Slide 5: Financial History
Financial History IPO : 1998 Euronext (FR 000 517 5080) and Nasdaq (TRGNY) Net proceeds of € 94 M Follow on : 2001; Net proceeds of € 63 M Mérieux Group Shareholders: (70.3%) (2.2%) Areva Free Float (2.1%) French Muscular Dystrophy (24.9%) Association Financials: Market capitalization: € 77,93 M as
Slide 6: Transgene Transformed
Transgene Transformed § December, 2004: New CEO with strong biotech experience and track record § February, 2005: New CSO with impressive background in immunology and oncology. § March, 2005: Company refocused on immunotherapy to treat infectious diseases and cancer § May, 2005: Strong Phase II data
Slide 7: Strategic direction: To become a leader in Immunotherapy and Therapeutic Vaccines
G3 Strategic direction:To become a leader in Immunotherapy and Therapeutic Vaccines § Large untapped market with no established entrenched players § Vaccine is getting market appreciation on the back of post-9/11 vaccine boom § Recent clinical progress has brought focus to the cancer vaccine market
Slide 8: Diapositive 7 G3
Diapositive 7 G3 Gabriel; 17/05/2005
Slide 9: Transgene in 2007
-- Transgene in 2007 -- § Three Phase III trials ongoing: • MVA-Muc1-IL2 to treat NSCLC • MVA-HPV-IL2 in CIN2/3 related to HPV16 • Ad-IFNg to treat cutaneous T cell lymphoma (CTCL) § MVA Muc1-IL2 in Prostate in Phase IIb § MVA-HCV in Phase II to treat chronic carriers § Partnerships for two of the P
Slide 10: 2005 Active Clinical Development Plan
2005 Active Clinical Development Plan Indication Preclinical Phase I Phase II Next step MVA-MUC1-IL2 Lung Phase IIb MVA-HPV-IL2 CIN 2/3 (6 month follow up) Phase IIb Ad-IFNγ Cutaneous T-Cell Lymphoma (CTCL) Phase II / III MVA-HCV Hepatitis C Phase I / II Myodys® Duchenne / Becker muscular dystrophy
Slide 11: Short term priorities
Short term priorities § Focus resources and capabilities towards achieving clinical proof of concept on most promising product and indications. § Exploit commercial opportunities for proprietary Phase II products (outlicensing after Phase II) § Re-deploy research program to support product strategy
Slide 12: Latest Clinical Developments
Latest Clinical Developments 11 transgene
Slide 13: MVA-MUC1-IL2 Product profile
MVA-MUC1-IL2 Product profile § Recombinant MVA (Modified Virus Ankara) • non-replicative, highly immunogenic poxvirus § Expressing MUC1 tumor-associated antigen • MUC1 is found in most adenocarcinoma • Associated with poor prognosis Cell membrane § Expressing human IL-2 cDNA GalNAc Sialic Ac (Tn) ST
Slide 14: MUC1 Expression in Major Cancers
MUC1 Expression in Major Cancers 90,0% 60,0% 60,0% MUC1+ MUC1+ MUC1+ Breast Lung Prostate 70,0% 80,0% 90,0% MUC1+ MUC1+ MUC1+ Colorectal Stomach Liver (cholangiocarcinoma) 13 transgene
Slide 15: MVA-MUC1-IL2 Phase II Results (ASCO, May 2005)
MVA-MUC1-IL2 Phase II Results (ASCO, May 2005) § End points reached in Non Small-cell Lung Cancer MVA-Muc1-IL2 + chemo : 35 evaluable patients 13/35 (37%) PR (validated by central reading) 12/35 (34%) SD > 12w 25/35 (71%) Clinical benefit 1-year survival: 53 % Median Time to Progression: 6.4 months
Slide 16: MVA-MUC1-IL2 in NSCLC: Comparison With Published Clinical Studies
MVA-MUC1-IL2 in NSCLC : Comparaison With Published Clinical Studies Using Navelbine / Cisplatine regimen Study % response Study TTP Study Overall survival (months) (months) Gebbia 44 MVA-Muc1-IL2 + 6.4 MVA-Muc1-IL2 + >13 MVA-Muc1-IL2 + 37 % chemo chemo chemo Gridelli 5.3 Fossela 10.1 Souquet 34.6 Fo
Slide 17: MVA-MUC1-IL2 Future direction
MVA-MUC1-IL2 Future direction § Proven biological activity by slowing down or stopping the growth of tumour of several origins § Most encouraging results obtained in lung cancer with possible synergy between MVA-MUC1-IL2 and chemotherapy § Next step: to demonstrate clinical benefit in lung cancer pa
Slide 18: MVA-HPV-IL2 Product profile
MVA-HPV-IL2 Product profile § Recombinant MVA (Modified Virus Ankara) • non-replicative, highly immunogenic poxvirus § Expressing early genes of Human Papilloma Virus 16 (HPV16) • CIN (cervical intraepithelial neoplasia) due to HPV: pre-cancerous stage of cervix cancer • “HPV is the necessary cause
Slide 19: MVA-HPV-IL2 Potential product positioning
MVA-HPV-IL2 Potential product positioning HPV infection Prophylaxis Persistent infection CIN2-3 Late-stage Cervix Cancer Surgery No vaccine No treatment Chemotherapy (conisation) L1 ± L2 E1 ± E2 E7 ± E6 ± E1 E7 ± E6 18 transgene
Slide 20: Incidence: HPV-related diseases
Incidence: HPV-related diseases Europe/US HPV16 Worldwide Cervix cancer 80,000 50% 470,000 CIN2/3 700,000 50% 1,400,000 CIN1 1,400,000 20% 14,000,000 Silent infection 14,000,000 20% 420,000,000 19 transgene
Slide 21: MVA-HPV-IL2 Clinical Trial Design - Completed Phase II
MVA-HPV-IL2 Clinical Trial Design - Completed Phase II § Multicenter study in France § CIN2/3 in HPV16+ patients § 3 sub-cutaneous injections of MVA-HPV-IL2, on Days 1-8-15 § 2 doses tested: 5x105 pfu and 5x107 pfu § Standard treatment (conisation) on Week 6-8 20 transgene
Slide 22: MVA-HPV-IL2 Final Results of Completed Phase II
MVA-HPV-IL2 Final Results of Completed Phase II Summary table of MVA-HPV-IL2 dose (pfu) secondary efficacy endpoints 5x105 5x107 Patients treated 14 17 Patients analyzed for efficacy 13 16 Viral clearance 0 4 Partial regression of histology signs 0 5 Reduction of grade (to CIN1) 0 2 Limited extent o
Slide 23: MVA-HPV-IL2 Clinical Trial Design - Phase IIb - Ongoing
MVA-HPV-IL2 Clinical Trial Design - Phase IIb - Ongoing § CIN2/3 in HPV 16-positive patients § Study design • Open-label, 5x107 pfu • 18 CIN2/3 patients § Treatment plan • Up to 6-month assessment period to study efficacy • Follow-up every 2 months : Cytology + virology + colposcopy ± biopsy • Respo
Slide 24: Ad-IFNγ Product Profile
Ad-IFNγ Product Profile § Recombinant adenovirus vector containing the sequence coding for the human IFN-g § Mechanism of action • Direct action on tumor cells: antiproliferative, induction of apoptosis • Indirect actions on tumors: immune stimulation, antiangiogenic activities § Clinical positionin
Slide 25: Ad-IFNγ Clinical Trial Design
Ad-IFNγ Clinical Trial Design Phase I/II : Primary Cutaneous Lymphoma § Study design Dose escalation 3 dose levels 3.109 tp → 3.1011 tp 3 patients / dose level (Phase I) + 9 patients at highest dose + up to 18 patients (Phase I / II) § Treatment plan Intra-tumoral administration Weekly injections (D
Slide 26: Ad-IFNγ Efficacy Results – February 28, 2005
Ad-IFNγ Efficacy Results – February 28, 2005 § Interim data first 20 patients • Clinical responses observed locally 7 CR and 3 PR out of 18 evaluable patients (56%) • Distant clinical responses : 2 CR – 1 PR out of 12 evaluable patients • Overall response rate (53%) 25 transgene
Slide 27: Ad-IFNγ Market potential
Ad-IFNγ Market potential CTCL Patients with limited number of lesions and refractory / relapsing to at least two lines of standard therapy Population incidence is estimated at 38.000 in Europe and US Hepato Cellular Carcinoma Worldwide incidence is estimated at 600.000 Population incidence is estima
Slide 28: Ad-IFNγ Future Direction
Ad-IFNγ Future Direction § Clinical development Cutaneous Lymphoma: • Final Results of Phase I/II in Q4 2005 • Phase II / III study (Q1 06 – Q1 08) in CTCL patients • Placebo controlled – 2 step study – 75 patients § Regulatory strategy :Finalise Design of next step with FDA and EMEA by mid 05. EMEA
Slide 29: Phase I & Preclinical Pipeline
Phase I & Preclinical Pipeline § MVA-HCV monotherapy (pre-clinical) • Chronic carriers (naïve and non-responders) • Start US Phase I/II trials in Q1 2006 • Phase II expected to begin by early 2007 • Prime-boost combinations under investigation in preclinicals. § Duchenne muscular dystrophy (phase I)
Slide 30: Financial Information
FINANCIAL INFORMATION 29 transgene
Slide 31: Statement of Operations
Statement of Operations US GAAP; in € million ; unaudited 2004 Revenues 2.5 Operating expenses (24.2) R&D (20.0) G&A (4.2) Loss from operations (21.7) Interest income 0.5 Income tax benefit 0.7 Net loss (20.5) Cash 14.6 2004 burn rate: 20.3 M€ 2005 expected burn rate: 20.0 M€ 30 transgene
Slide 32: Conclusion
CONCLUSION 31 transgene
Slide 33: Milestones and Newsflow
Milestones and Newsflow PRODUCT INDICATION MILESTONE DATE ASCO presentation of results for Lung & Prostate May 16-17, 2005 MVA-MUC1-IL2 NSCLC / Lung Start of Phase IIb trial Q4 2005 MVA-HPV-IL2 CIN 2/3 Results on Phase II trial Q4 2005 Feedback on pivotal design by agencies Q2 2005 Ad-IFNg CTCL Fina
Slide 34: Investment case
Investment case § Therapeutic vaccines are becoming increasingly attractive for large pharma (Serono, Pfizer …) § Clinical pipeline with 3 phase II in active development will provide near term partnering opportunities § Products in attractive indications and with large market potential aiming at ful
Slide 35: Senior Management
Senior Management Dr. Christophe MERIEUX Philipe ARCHINARD Chairman Chief Executive Officer Philippe PONCET Jean-Yves BONNEFOY Chief Scientific Officer Chief Financial Officer 34 transgene
Slide 36: Transgene contact details
Transgene 11 rue de Molsheim 67082 Strasbourg Cedex France Contact : communication@transgene.fr Tel : +33-(0)3.88.27.91.02 Web Site : www.transgene.fr 35 transgene